Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Comparative activity of plazomicin against extended-spectrum cephalosporin-resistant Escherichia coli clinical isolates (2012–2017) in relation to phylogenetic background, sequence type 131 subclones, blaCTX-M genotype, and resistance to comparator agents

European Journal of Clinical Microbiology & Infectious Diseases(2021)10.1007/s10096-021-04256-9Source: DataRank Database

Comparative activity of plazomicin against extended-spectrum cephalosporin-resistant Escherichia coli clinical isolates (2012–2017) in relation to phylogenetic background, sequence type 131 subclones, blaCTX-M genotype, and resistance to comparator agents is a research paper published in European Journal of Clinical Microbiology & Infectious Diseases (2021). On theSindex it has a DataRank of 0. It has been cited 3 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access3 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Impact (FWCI 0.14)OA: greenTopics (63)IDs (PubMed, PMC, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (5)

Paul Thuras ORCID,Stephen B. Porter ORCID,Connie Clabots,James R. Johnson ORCID,Brian Johnston ORCID

Live enrichment

PubMed:33893571 PMC:PMC8449799 OpenAlex:https://openalex.org/W3155146097

NIAID NIH HHS

Grant: UM1 AI104681

Intramural VA

Grant: VA999999

National Institutes of Health

Grant: 5UM1AI104681-03

Antibacterial Resistance Leadership Group (ARLG)

achaogen/cipla

FWCI

0.14

Citation Percentile

0.3%

Citation Trend

2021

2022

2026

greenLicense: Springer TDM

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/8449799

publisherhttps://link.springer.com/content/pdf/10.1007/s10096-021-04256-9.pdf

publisherhttps://link.springer.com/article/10.1007/s10096-021-04256-9/fulltext.html

journalhttps://doi.org/10.1007/s10096-021-04256-9

Fields of Study

Antibiotic Resistance in BacteriaBacterial Identification and Susceptibility TestingAntibiotics Pharmacokinetics and Efficacy0301 basic medicine03 medical and health sciences0302 clinical medicine

MeSH Terms

MeropenemAdultAgedAged, 80 and overAnti-Bacterial Agentsbeta-LactamasesCephalosporinsEscherichia coliEscherichia coli InfectionsFemaleGenotypeHumansMaleMicrobial Sensitivity TestsMiddle AgedPhylogenySisomicinImipenemDrug Resistance, Multiple, BacterialEscherichia coli ProteinsYoung Adult

Keywords

AmikacinMicrobiologyBiologyAminoglycosideEscherichia coliGenotypeTigecyclineAntimicrobialTobramycinAntibioticsGeneticsGeneGentamicinAntimicrobial resistanceExtended-spectrum beta-lactamaseSt131Extended-spectrum CephalosporinsPlazomicinAdultAged, 80 and overMaleEscherichia coli ProteinsMeropenemMicrobial Sensitivity TestsMiddle AgedAnti-Bacterial AgentsCephalosporinsImipenemYoung AdultDrug Resistance, Multiple, BacterialSisomicinHumansFemaleEscherichia coli InfectionsPhylogenyAged

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Life in Land